Eli Lilly, the maker of hugely popular weight loss drugs, has reached $1 trillion in value, becoming the first publicly ...

Eli Lilly stock soars on obesity drug success. See here to know why LLY remains a top pick with strong growth prospects and a ...

Danish drugmaker Novo Nordisk A/S was at the forefront of the weight-loss injection boom as people discovered that its ...

Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by ...

That said, GLP-1 medications for weight loss are not for everyone, and they can cause unpleasant, even serious, side effects, ...

Researchers monitoring the brain activity of a patient with a severe binge-eating problem reported that Eli Lilly's GLP-1 ...

Weight-loss drugs like Wegovy and Zepbound often cause nausea and other side effects. Brain scientists are looking for ways ...

Next generation weight loss drugs are prohibitively expensive for many in the US who would benefit from taking them—and may remain so, thanks to the phenomenon of patent thickets. Paige Huffman ...

Eli Lilly posts 54% revenue growth with Zepbound, Mounjaro, expanding pipeline, and rising market share. Learn why LLY stock ...

GLP-1s are being studied for a wide range of conditions. Now, scientists will test whether their anti-inflammatory properties ...

Andy Richter credits GLP-1 medication, Zepbound for his 'DWTS' weight loss while praising the show's exercise impact and ...

One of the biggest gripes around weight loss medications like Wegovy and Zepbound is the high price tag. At $1,000 or more a ...